ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing ...

"I've been working international fugitives with the FBI about 26 years… we've arrested a lot of bad guys," says FBI Special Agent Phil Torsney. "This is a once-in-a-lifetime case…and it was certainly ...

After more than a year of preparation, the Every Student Succeeds Act is on the verge of hitting classrooms nationwide. And nearly all states have now laid out their blueprints for how they intend to ...

When President Barack Obama signed the Every Student Succeeds Act on Dec. 10, 2015, he called it a “Christmas miracle.” The law, which replaced the much-criticized No Child Left Behind Act, ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...

In December 2015, Congress passed the Every Student Succeeds Act (ESSA) amid strong bipartisan support. The House passed the bill by 359–64, and seven days later the Senate passed the bill 85–12; ...

ESSA Pharma (EPIX) is a Canadian developer of therapies directed specifically at prostate cancer. This is interesting because it is quite rare to see a biotech that's this focused, and that makes it ...

STROUDSBURG, Pa.--(BUSINESS WIRE)--ESSA Bancorp, Inc. (NASDAQ Global Market SM “ESSA”), the parent company of ESSA Bank & Trust, and First Star Bancorp, Inc., (Pinksheets: FSSB), the parent company of ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...